These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 18156171

  • 1. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.
    J Clin Oncol; 2007 Sep 01; 25(25):3892-901. PubMed ID: 17679727
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.
    J Clin Oncol; 2006 Feb 20; 24(6):937-44. PubMed ID: 16418495
    [Abstract] [Full Text] [Related]

  • 4. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK.
    Br J Haematol; 2009 Jan 20; 144(2):169-75. PubMed ID: 19036114
    [Abstract] [Full Text] [Related]

  • 5. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ.
    Am J Hematol; 2009 Oct 20; 84(10):657-60. PubMed ID: 19731393
    [Abstract] [Full Text] [Related]

  • 6. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG, Jin J, Huang XJ, Li Y, Chen WM, Liu ZG, Chen XQ, Shen ZX, Hou J.
    Chin Med J (Engl); 2011 Oct 20; 124(19):2969-74. PubMed ID: 22040537
    [Abstract] [Full Text] [Related]

  • 7. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
    Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J.
    Br J Haematol; 2005 Jun 20; 129(6):776-83. PubMed ID: 15953004
    [Abstract] [Full Text] [Related]

  • 8. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA.
    Cancer; 2008 Aug 15; 113(4):765-71. PubMed ID: 18543319
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.
    J Clin Oncol; 2010 Oct 20; 28(30):4635-41. PubMed ID: 20823423
    [Abstract] [Full Text] [Related]

  • 12. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, Ackerman E, Berenson JR.
    Ann Hematol; 2011 Feb 20; 90(2):193-200. PubMed ID: 20809423
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators.
    Cancer; 2008 Apr 01; 112(7):1529-37. PubMed ID: 18300257
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF, Deng SH, Wu T, Xu Y, Zou DH, Wang Y, Zhao YZ, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun 01; 29(6):397-400. PubMed ID: 19031743
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
    Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM.
    Intern Med J; 2009 May 01; 39(5):290-5. PubMed ID: 19371392
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.